Symposium - Is medical treatment of coronary artery disease superior to revasculation procedures?, Vancouver, BC, Canada, 31 May 1997: Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis treatment study design

Canadian Journal of Cardiology

Volumn 14, Issue SUPPL. A, 1998, Pages

  Brown, B Greg ^a   Zhao, Xue Qiao ^b   Chait, Alan ^b   Frohlich, Jiri ^b   Cheung, Marian ^b   Heise, Nancy ^b   Dowdy, Alice ^b   DeAngelis, Debbie ^b   Fisher, Lloyd D ^b   Albers, John ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

Coronary artery disease; HDL Atherosclerosis Treatment Study; High density lipoprotein cholesterol

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; SIMVASTATIN; VITAMIN;

ADULT; AGED; ANGIOGRAPHY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL; SYMPOSIUM; ANGIOCARDIOGRAPHY; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; MIDDLE AGED; REVIEW; TREATMENT OUTCOME;

ADULT; AGED; ANTILIPEMIC AGENTS; ANTIOXIDANTS; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOVASTATIN; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; NIACIN; SIMVASTATIN; TREATMENT OUTCOME; VITAMINS;

EID: 0032041991     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma. Am J Med 1951;11:480-93.
2. Gordon T, Castelli W, Hjortland MC, Kannel WB, DawberTR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977;62:707-14.
3. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective studies. Circulation 1989;79:8-15.
4. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein levels: The Framingham study. JAMA 1986;256:2835-8.
5. Heiss G, Johnson NJ, Reiland S, Davie CE, Tyroler HA. The epidemiology of plasma high-density lipoprotein cholesterol levels: The Lipid Research Clinics Prevalence Study: Summary. Circulation 1980;62(Suppl IV):IV116-36.
6. The Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
7. Watkins LO, Neaton JD, Kuller LH (for the MRFIT Research Group). Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the Usual-Care group of the Multiple Risk Factor Intervention Trial. Am J Cardiol 1986;57:538-45.
8. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
9. Johansson J, Carlson LA, Landiu C, Hamsten A. High density lipoproteins and coronary atherosclerosis: a strong inverse relation with the largest particles is confined to normotriglycendemic patients. Arterioscler Thromb 1991;11:174-82.
10. Blankenhorn DH, Johnson RL, Mack WJ, Zein HA, Vaolas LI. The influence of diet on the appearance of new lesions in human coronary arteries. JAMA 1990;263:1646-52.
11. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-70.
12. Brown BG, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
13. Stewart BF, Brown B, Zhao X-Q, et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol 1994;23:899-906.
14. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of besafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-59.
15. Le NA, Ginsberg HN. Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism 1988;37:614-7.
16. Schaefer EJ, Ordovas JM, Law SW, et al. Familial apolipoprotein A-I and C-III deficiency. Variant II. J Lipid Res 1985;26:1089-101.
17. Miller NE. Raising high density lipoprotein cholesterol. The biochemical pharmacology of reverse cholesterol transport. Biochem Pharmacol 1990;40:403-10.
18. Schaefer EJ. Clinical, biochemical, and genetic features in familial disorders or high density lipoprotein deficiency. Arteriosclerosis 1984;4:303-22.
19. Paigen B, Nesbitt MN, Mitchell D, Albee D, LeBouef RC. Ath-2, a second gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Genetics 1989;122:163-8.
20. Walsh A, Ito Y, Breslow JL. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human. J Biol Chem 1989;264:6488-92.
21. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 1991;353:265-7.
22. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993;261:469-72.
23. Maher VMG, Brown BG, Zhao X-Q, et al. Contrasting effects of apoproteins A-I and A-II on coronary artery disease change in men during 2.5 years of lipid-lowering therapy. J Am Coll Cardiol 1994;23(Suppl A):100A. (Abst)
24. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography: particles containing AI and AII and particles containing AI but not All. J Biol Chem 1984;259:12201-9.
25. Cheung MC, Brown BG, Wolf AC, Albers JJ. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991;32:383-94.
26. Dobiasova M, Stribma J, Sparks DL, Pritchard PH, Frohlich JJ. Cholesterol esterfication rates in VLDL- and LDL-depleted plasma. Relation to HDL subspecies, sex, hyperlipidemia, and coronary disease. Arterioscler Thromb 1991;11:64-70.
27. Schaffner T, Taylor K, Bartucci EJ, et al. Arterial foam cells with distinctive immunomorphologic and histochemical features of macrophages. Am J Pathol 1980;100:57-80.
28. Gerrity RG. The role of monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981;103:181-90.
29. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phosphohpids. Proc Natl Acad Sci USA 1984;81:3883-7.
30. Heinecke JW, Baker L, Rosen L, Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J Clin Invest 1986;77:757-61.
31. Goldstein JL, How YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979;76:333-7.
32. Berliner JA, Territo MC, Sevanian A, et al Minimally modified LDL stimulates monocyte endothelial interactions. J Clin Invest 1990;85:1260-6.
33. Hessler JR, Morel DW, Lewis LJ, Chisolm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 1983;3:215-22.
34. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344:160-2.
35. Fox PL, Chisolm GM, DiCorleto PE. Lipoprotein-mediated inhibition of endothelial cell production of platelet-derived growth factor-like protein depends on free radical lipid peroxidation. J Biol Chem 1987;262:6026-54.
36. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-95.
37. Palinski W, Rosenfeld ME, Yla-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989;86:1372-6.
38. Haberland M, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988;24:215-8.
39. Jialal I, Norkus EP, Cristol LS, Grundy SM. Inhibition of LDL oxidation by beta-carotene. Circulation 1991;84(Suppl II):II449. (Abst)
40. Jialal I, Grundy SM. Preservation of endogenous antioxidants in low density lipoprotein by ascorbate but not probucol during oxidative modification. J Clin Invest 1991;87:597-601.
41. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725-9.
42. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35.
43. Jialal I, Norkus EP, Cristol LS, Grundy SM. Inhibition of LDL oxidation by beta-carotene. Circulation 1991;84(SuppI II):I1449. (Abst)
44. Parthasarathy S, Bamett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochem Biophys Acta 1990;1044:275-83.
45. Douste-Blazy L, N'egre-Salvayre A, Lopez M, Salvayre R. The cytotoxicity of oxidized lipoproteins. Bull Acad Natl Med 1989;173:903-10.
46. Walldius G, Erikson LJ, Olsson AG, et al. The effect of probucol on femeral atherosclerosis: The Provocol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83.
47. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993;269:3015-23. (Comment)
48. Esterbauer H, Streigl G, Puhl H. Continuous monitoring of in vitro oxidation of human LDL. Free Radic Res Commun 1989;6:67-75.
49. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982;23:97-104.
50. Brown BG, Hillger LA, Lewis C, et al A maximum confidence approach for measurement of progression and regression of coronary artery disease in clinical trials. Circulation 1993;87(Suppl II):II66-73.